Prescribing patterns of allopurinol and febuxostat according to directives on the reimbursement criteria and clinical guidelines: analysis of a primary care database (original) (raw)

Current medical research and opinion, 2018

Abstract

Objective According to American clinical guidelines, allopurinol and febuxostat may be prescribed as first-line therapy to treat hyperuricemia. However, the Italian Medicines Agency directive, called Nota 91, allows the reimbursement of second-line febuxostat in case of failure and/or intolerance of a previous allopurinol therapy, so partially embracing European League Against Rheumatism recommendations and the British Society for Rheumatology Guideline. Such inconsistency might lead to heterogeneity among General Practitioners (GPs) in treatment of hyperuricemia. This study therefore aimed to evaluate the prescribing behavior of GPs in terms of compliance with Nota 91 and/or official guidelines. Methods Using the Health Search Database, a retrospective cohort study was conducted to evaluate the patterns of use of allopurinol and febuxostat between 2011 and 2016. Results 44,257 and 5,837 patients were prescribed with allopurinol and febuxostat, respectively. Among febuxostat users, ...

Giada Crescioli hasn't uploaded this paper.

Let Giada know you want this paper to be uploaded.

Ask for this paper to be uploaded.